Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Jan 28, 2005; 11(4): 538-544
Published online Jan 28, 2005. doi: 10.3748/wjg.v11.i4.538
Published online Jan 28, 2005. doi: 10.3748/wjg.v11.i4.538
Group | FCD (cm-1) | Calibrated FCD (cm-1) |
Normal control | 22.93±5.189 | |
Caerulein-induced pancreatitis | 25.71±3.398a | 34.4 |
Sodium taurocholate-induced pancreatitis | 21.9±5.681 | 36.51 |
PACAP 5 μg | 21.68±4.268 | 24.49 |
PACAP 10 μg | 19.52±3.837a | 22.98 |
PACAP 15 μg | 19.6±4.949a | 23.97 |
PACAP 30 μg | 18.56±6.021a | 21.53 |
Sodium taurocholate+PACAP 10 μg | 18.71±3.383a | 26.19 |
Caerulein+PACAP15 μg | 22.68±3.62 | 37.51 |
Caerulein+PACAP 30 μg | 18.28±3.772a | 39.7 |
- Citation: Chen YD, Zhou ZG, Wang Z, Gao HK, Yan WW, Wang C, Zhao GP, Peng XH. Pituitary adenylate cyclase activating-peptide and its receptor antagonists in development of acute pancreatitis in rats. World J Gastroenterol 2005; 11(4): 538-544
- URL: https://www.wjgnet.com/1007-9327/full/v11/i4/538.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i4.538